Skip to main content
Merck10-Q: Capex increase

Merck's investing cash usage surged to $10.2B, driven by acquisitions of Cidara and Terns

What happened

Merck's cash used for investing increased nearly 7x year-over-year, primarily for acquisitions like Cidara and the upcoming $6.7B purchase of Terns.

Source

SEC EDGARMay 4, 2026

Quarterly report (Form 10-Q)

Merck 10-Q

Filing excerpt

Cash used in investing activities was $10.2 billion in the first three months of 2026 compared with $1.5 billion in the first three months of 2025. The higher use of cash in investing activities was primarily due to the acquisition of Cidara...

sec.gov/Archives/edgar/data/310158/000162828026029802/mrk-20260331.htmRead the full source

Other signals in this filing (11)

Extracted by Autobound

From the Signal API record
Signal
10-Q: Capex increase

What this signalsFilings often name leadership changes, deals and spending plans.

Fiscal year end
03/31
Filed
May 4, 2026

More 10-Q signals at other companies

The full record

From the Signal API record

Numbers

Dollar figure
$10.2B (Cash used in investing activities in Q1 2026)

Details

CIK
310158
Accession number
0001628280-26-029802
Timeframe
Current quarter
Filing year
2026
Fiscal year
0
Why it matters
Budget available
Signal category
Financial

Topics and mentions

Vendors

  • Cidara Therapeutics Inc.
  • Terns Pharmaceuticals Inc.
  • WuXi Vaccines

Extraction

Confidence
High
Relevance
90%
Sentiment
Positive
Detected
May 5, 2026
signal_type
sec-10q
signal_subtype
capexIncrease

Use this data

Get every 10-Q signal for Merck and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Merck this week?”

  2. Send it to your own tools

    The Signal API returns 10-Q signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full sec-10q record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/6f798f5d-bae3-44d2-b081-061e5d1f94c7 returns this record as JSON. POST /v1/companies/enrich returns every signal for merck.com.

{
  "signal_id": "6f798f5d-bae3-44d2-b081-061e5d1f94c7",
  "signal_type": "sec-10q",
  "signal_subtype": "capexIncrease",
  "detected_at": "2026-05-05T08:48:22.077+00:00",
  "company": {
    "name": "Merck",
    "domain": "merck.com"
  },
  "data": {
    "detail": "Merck's cash used for investing increased nearly 7x year-over-year, primarily for acquisitions like Cidara and the upcoming $6.7B purchase of Terns. Integrating these new companies will create immediate needs for harmonizing IT infrastructure, HR systems, and financial reporting, presenting opportunities for consulting and enterprise software vendors.",
    "metrics": {
      "timeframe": "current_quarter",
      "dollar_context": "Cash used in investing activities in Q1 2026",
      "dollar_millions": 10200
    },
    "summary": "Merck's investing cash usage surged to $10.2B, driven by acquisitions of Cidara and Terns",
    "excerpts": "Cash used in investing activities was $10.2 billion in the first three months of 2026 compared with $1.5 billion in the first three months of 2025. The higher use of cash in investing activities was primarily due to the acquisition of Cidara...",
    "relevance": 0.9,
    "sentiment": "positive",
    "confidence": "high",
    "source_url": "https://www.sec.gov/Archives/edgar/data/310158/000162828026029802/mrk-20260331.htm",
    "filing_date": "2026-05-04",
    "filing_year": 2026,
    "fiscal_year": 0,
    "fiscal_year_end": "03/31",
    "sales_relevance": "Budget available",
    "signal_category": "financial",
    "vendors_mentioned": [
      "Cidara Therapeutics Inc.",
      "Terns Pharmaceuticals Inc.",
      "WuXi Vaccines"
    ]
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.